2633 — Jacobson Pharma Share Price
0.000.00%
Last trade - 00:00- HK$2.32bn
- HK$2.53bn
- HK$1.47bn
- 89
- 84
- 96
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | 1.16 | ||
| Price to Free Cashflow | 6.96 | ||
| Price to Sales | 1.49 | ||
| EV to EBITDA | 4.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.74% | ||
| Return on Equity | 10.75% | ||
| Operating Margin | 23.22% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 1,571.46 | 1,445.91 | 1,595.54 | 1,267.6 | 1,467.8 | n/a | n/a | -0.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -16.29 | -38.17 | +44.67 | +4.01 | +11.78 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jacobson Pharma Corporation Ltd is an investment holding company principally engaged in the manufacturing and sale of generic drugs. The Company operates its business through two segments. The Generic Drugs segment is engaged in the development, manufacture and distribution of a host of off-patent medicines for various therapeutic use. The Branded Healthcare segment is engaged in the development, manufactures and distributes branded medicines, proprietary Chinese medicines and health and wellness products. Currently the activities of two segments in this regard are primarily carried out in Hong Kong.
Directors
- Kwong Yip Sum CHM (58)
- Chun Kau Yu CFO (48)
- Celine Heung Kwan Cheng EVP (54)
- Yu Sun Wong EVP (45)
- Kin Man Chan VPR (53)
- Chi Shing Cheng VPR (32)
- Ka Wing Chu VPR (47)
- Tak Chuen Chui VPR (32)
- Yue Wai Pun VAD (65)
- Chun Leung Yim EDR (59)
- Chi Kei Wong NED (54)
- Kwing Tong Lam NID (54)
- Sing Kw Lam NID (62)
- Chun Man Young NID (58)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- January 1st, 1970
- Public Since
- September 21st, 2016
- No. of Employees
- 1,730
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,985,721,000
- Address
- Unit 2313-18, 23/F,
- Web
- http://www.jacobsonpharma.com/
- Phone
- +852 null22672298
- Auditors
- KPMG CPA
Upcoming Events for 2633
Similar to 2633
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
FAQ
What is the Jacobson Pharma share price?
As of Today at 20:25 UTC, shares in Jacobson Pharma are trading at HK$1.17. This share price information is delayed by 15 minutes.
How has the Jacobson Pharma share price performed this year?
Shares in Jacobson Pharma last closed at HK$1.17 and the price had moved by +91.8% over the past 365 days. In terms of relative price strength the Jacobson Pharma share price has outperformed the FTSE Developed Asia Pacific Index by +98.2% over the past year.
What are the analyst and broker recommendations for Jacobson Pharma?
The overall consensus recommendation for Jacobson Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Jacobson Pharma dividend yield?
The Jacobson Pharma dividend yield is 5.56% based on the trailing twelve month period.
Does Jacobson Pharma pay a dividend?
Last year, Jacobson Pharma paid a total dividend of HK$0.07, and it currently has a trailing dividend yield of 5.56%.Looking ahead, the next dividend pay date is 2025-04-02.
When does Jacobson Pharma next pay dividends?
We do not have data on when Jacobson Pharma is to next pay dividends. The historic dividend yield on Jacobson Pharma shares is currently 5.56%.
How do I buy Jacobson Pharma shares?
To buy shares in Jacobson Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jacobson Pharma?
As of the previous close price of HK$1.17, shares in Jacobson Pharma had a market capitalisation of HK$2.32bn.
Where are Jacobson Pharma shares listed?
Here are the trading details for Jacobson Pharma:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2633
What kind of share is Jacobson Pharma?
Based on an overall assessment of its quality, value and momentum Jacobson Pharma is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jacobson Pharma share price forecast for 2025?
The analyst consensus target price for shares in Jacobson Pharma is HK$1.30. That is 11.11% above the last closing price of HK$1.17.
Analysts covering Jacobson Pharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Jacobson Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jacobson Pharma. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +109.34%.
As of the last closing price of HK$1.17, shares in Jacobson Pharma were trading +44.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jacobson Pharma PE Ratio?
The Jacobson Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jacobson Pharma?
Jacobson Pharma's management team is headed by:
- Kwong Yip Sum - CHM
- Chun Kau Yu - CFO
- Celine Heung Kwan Cheng - EVP
- Yu Sun Wong - EVP
- Kin Man Chan - VPR
- Chi Shing Cheng - VPR
- Ka Wing Chu - VPR
- Tak Chuen Chui - VPR
- Yue Wai Pun - VAD
- Chun Leung Yim - EDR
- Chi Kei Wong - NED
- Kwing Tong Lam - NID
- Sing Kw Lam - NID
- Chun Man Young - NID